About Windlas
Windlas is a company based in Gurugram (India) founded in 2001 by Ashok Kumar Windlas and Manoj Kumar Windlass was acquired by Zydus Life in August 2018. Windlas has raised $12.96 million across 3 funding rounds from investors including HDFC Bank, HSBC and Kotak Mahindra Bank. The company has 1,350 employees as of March 31, 2024. Windlas offers products and services including Contract Manufacturing Services, Therapeutic Products, and Customized Formulations. Windlas operates in a competitive market with competitors including Unither, Akums, Jubilant Life Sciences, Recipharm and CoreRx, among others.
- Headquarter Gurugram, India
- Employees 1350 as on 31 Mar, 2024
- Founders Ashok Kumar Windlas, Manoj Kumar Windlass
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Windlas Biotech Ltd.
-
Annual Revenue
$88.84 M (USD)20.44as on Mar 31, 2025
-
Net Profit
$7.14 M (USD)4.82as on Mar 31, 2025
-
EBITDA
$11.08 M (USD)20.34as on Mar 31, 2025
-
Total Equity Funding
$12.96 M (USD)
in 3 rounds
-
Latest Funding Round
$2.45 M (USD), Debt – Conventional
Jun 01, 2021
-
Investors
HDFC Bank
& 5 more
-
Employee Count
1350
as on Mar 31, 2024
-
Acquired by
Zydus Life
(Aug 14, 2018)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Windlas
Windlas is a publicly listed company on the NSE with ticker symbol WINDLAS in India, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Windlas
Windlas offers a comprehensive portfolio of products and services, including Contract Manufacturing Services, Therapeutic Products, and Customized Formulations.
Provides contract development and production for pharmaceuticals
Offers formulations for health conditions like anti-diabetic and cardiovascular
Delivers tailored pharmaceutical solutions for clients
Funding Insights of Windlas
Windlas has successfully raised a total of $12.96M across 3 strategic funding rounds. The most recent funding activity was a Debt – Conventional round of $2.45 million completed in June 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Windlas
Windlas has secured backing from 6 investors, including institutional investors. Prominent investors backing the company include HDFC Bank, HSBC and Kotak Mahindra Bank.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Commercial and personal banking services are offered by HDFC Bank.
|
Locked | Locked | Locked | |
|
Universal banking and financial advisory services are provided globally.
|
Locked | Locked | Locked | |
|
Personal and business banking products and services are provided.
|
Locked | Locked | Locked |
Investor details for Windlas
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Windlas
Investment portfolio details for Windlas
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Windlas
Detailed financials for Windlas
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Windlas Comparisons
Peer comparison for Windlas
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Windlas
Windlas operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Unither, Akums, Jubilant Life Sciences, Recipharm and CoreRx, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Contract development and manufacturing organization for proprietary and generic drugs
|
|
| Locked | Locked | Locked |
CDMO focusing on spectrum of dosage forms and therapeutic segments
|
|
| Locked | Locked | Locked |
Company offering a suite of R&D and manufacturing services for small molecules and generics
|
|
| Locked | Locked | Locked |
Pharmaceutical development and manufacturing services are offered contractually.
|
|
| Locked | Locked | Locked |
CDMO with a focus on early phase drug product development
|
|
| Locked | Locked | Locked |
Cephalosporin APIs and generic formulations are manufactured.
|
Detailed competitors of Windlas
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Windlas
Complete news archive for Windlas
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Windlas
Windlas was founded in 2001 and raised its 1st funding round 14 years after it was founded.
Windlas is headquartered in Gurugram, India. It is registered at Gurugram, Haryana, India.
Komal Gupta is the current CEO of Windlas.
Windlas is a funded company, having raised a total of $12.96M across 3 funding rounds to date.
As of Mar 31, 2024, the latest employee count at Windlas is 1,350.
Annual revenue of Windlas is $88.84M as on Mar 31, 2025.
Windlas was founded in 2001 and is headquartered in Gurugram, India. Regulatory affairs, quality control, and market strategy services are delivered to the biopharma sector by the company. Operations focus on supporting biopharma firms with compliance, testing, and strategic planning needs. Leadership includes co-founders Ashok Kumar Windlas and Manoj Kumar Windlass, alongside CEO Komal Gupta, whose details encompass DIN and PAN identifiers for corporate records.
Windlas's top competitors include Jubilant Life Sciences, Akums and Nectar Lifesciences.
Windlas offers Contract Manufacturing Services, Therapeutic Products, and Customized Formulations.
Yes, Windlas is publicly traded on NSE under the ticker symbol WINDLAS.
Windlas has 6 investors. Key investors include HDFC Bank, HSBC, Kotak Mahindra Bank, IndusInd Bank, and Zydus Life.
The ticker symbol of Windlas is WINDLAS on NSE.
The valuation of Windlas is $81.22M as of Aug 2015.